ConductScience.org, home

Paper42928005PubMed

[KASID Guidelines for the Medical Treatment of Crohn's Disease: 2026].

Shin SY and 22 others. Korean J Gastroenterol, 2026.

Cite this record

ConductScience Library. [KASID Guidelines for the Medical Treatment of Crohn's Disease: 2026]. Papers, record 42928005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42928005

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
[KASID Guidelines for the Medical Treatment of Crohn's Disease: 2026].
Journal
Korean J Gastroenterol
Year
2026
Publication types
English Abstract, Journal Article, Practice Guideline, Review
Revised in PubMed
2026-10-30

Source PubMed

Authors23

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shin SYSeung Yong
2Bae JHJune Hwa
3Kim DHDong Hyun
4Hong SMSeung Min
5Song EMEun Mi
6Kim JEJi Eun
7Yang YJYoung Joo
8Yoon JJiyoung
9Kang SBSang-Bum
10Kim ESEun Soo
11Kim SESeong-Eun
12Kim SJSeong-Jung
13Lee JJun
14Na SYSoo-Young
15Park SJSoo Jung
16Park SHSang Hyoung
17Kim MHMyung Ha
18Choi MMiyoung
19Lee JLJong Lyul
20Baek SJSe-Jin

Source PubMed

See all 23 authorsDownload CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Crohn DiseaseMajor topic
Humans
Biosimilar Pharmaceuticals
Immunomodulating Agents

References184

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125993693Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study.Inflamm Bowel Dis2015https://conductscience.org/library/papers/25993693PubMed
237089065Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.Aliment Pharmacol Ther2023https://conductscience.org/library/papers/37089065PubMed
332648579Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.J Crohns Colitis2020https://conductscience.org/library/papers/32648579PubMed
440717455Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease.Aliment Pharmacol Ther2025https://conductscience.org/library/papers/40717455PubMed
532881046Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease.J Gastroenterol Hepatol2021https://conductscience.org/library/papers/32881046PubMed
640243842Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).J Crohns Colitis2025https://conductscience.org/library/papers/40243842PubMed
729363534Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study.Gut2019https://conductscience.org/library/papers/29363534PubMed
831892912Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease.Gastroenterol Hepatol (N Y)2019https://conductscience.org/library/papers/31892912PubMed
930656288Budesonide for the Induction and Maintenance of Remission in Crohn's Disease: Systematic Review and Meta-Analysis for the Cochrane Collaboration.J Can Assoc Gastroenterol2018https://conductscience.org/library/papers/30656288PubMed
1032733600Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial.Ther Adv Gastroenterol2020https://conductscience.org/library/papers/32733600PubMed
1135987302Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.Clin Gastroenterol Hepatol2023https://conductscience.org/library/papers/35987302PubMed
1227713072GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT.J Clin Epidemiol2017https://conductscience.org/library/papers/27713072PubMed
1336245343Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease.Intest Res2023https://conductscience.org/library/papers/36245343PubMed
14402551455-Aminosalicylates for non-surgical patients with active or quiescent Crohn's disease: an overview of systematic reviews (umbrella review).J Crohns Colitis2025https://conductscience.org/library/papers/40255145PubMed
1520393175Infliximab, azathioprine, or combination therapy for Crohn's disease.N Engl J Med2010https://conductscience.org/library/papers/20393175PubMed
1610228190Infliximab for the treatment of fistulas in patients with Crohn's disease.N Engl J Med1999https://conductscience.org/library/papers/10228190PubMed
1738402895
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Lancet Gastroenterol Hepatol2024https://conductscience.org/library/papers/38402895PubMed
1829471381Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2.J Crohns Colitis2018https://conductscience.org/library/papers/29471381PubMed
1921070781Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.Gastroenterology2011https://conductscience.org/library/papers/21070781PubMed
204143532Controlled trial of azathioprine in Crohn's disease.Lancet1971https://conductscience.org/library/papers/4143532PubMed

See all 184 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42928005

GET https://conductscience.org/api/papers/v1/42928005/authors?page=2